The epidemic of metabolic syndrome has
spread to every country. Obesity, hyperglycemia, and dyslipidemia are linked to
it. The aftereffects of this disorder raise mortality rates and the risk of
cardiovascular and neurological conditions. In addition to disrupting cellular
homeostasis, the pathogenesis of metabolic syndrome is linked to dysregulation
of redox and inflammatory state. It has been demonstrated that molecular
hydrogen (H2) lowers oxidative stress, enhances cellular performance, and
lowers chronic inflammation. Although H2-rich water (HRW) has been demonstrated
in pre-clinical and clinical research to have positive effects on some aspects
of the metabolic syndrome, it is unknown how long-term, high-concentration HRW
would affect metabolic syndrome. 60 individuals with metabolic syndrome took
part in a randomised, double-blinded, placebo-controlled Following a one-week initial observation
period during which baseline clinical data were collected, participants were
randomly assigned to receive either a placebo or high-concentration HRW (>
5.5 millimoles of H2 per day) for 24 weeks. In comparison to placebo,
high-concentration HRW supplementation substantially decreased blood
cholesterol and glucose levels, attenuated serum haemoglobin A1c, and enhanced
inflammatory and redox homeostasis indicators (P 0.05). H2 also caused a
considerable drop in blood pressure as well as a modest decrease in
waist-to-hip ratio and body mass index. These findings support earlier research
showing high-concentration HRW may have therapeutic effects in reducing risk
factors for metabolic syndrome and its associated complications.
Author(s) Details:
Tyler W. Le Baron,
Centre of Experimental Medicine, Institute for Heart Research, Slovak
Academy of Sciences, Bratislava, Slovak Republic and Molecular Hydrogen Institute, Enoch, Utah,
USA.
Ram B. Singh,
Hospital and Research Institute, Moradabad, India.
Ghizal Fatima,
Era Medical College, Lucknow, India.
Kumar Kartikey,
Hospital and Research Institute, Moradabad, India.
Jai P. Sharma,
Hospital and Research Institute, Moradabad, India.
Sergej M. Ostojic,
Applied Bioenergetics Lab, Faculty of Sport and PE, University of Novi Sad,
Novi Sad, Serbia and Faculty of Health
Sciences, University of Pecs, Pecs, Hungary.
Anna Gvozdjakova,
Pharmacobiochemical Laboratory of 3rd Medical Department, Medical Faculty,
Comenius University Bratislava, Bratislava, Slovakia.
Branislav Kura,
Molecular Hydrogen Institute, Enoch, Utah, USA.
Mami Noda,
Laboratory of Pathophysiology, Graduate School of Pharmaceutical Sciences,
Kyushu University, Fukuoka, Japan.
Viliam Mojto,
Third Internal Clinic, Faculty of Medicine, Comenius University, Bratislava,
Slovakia.
Mohammad Arif Niaz,
Center of Nutrition Research, International College of Nutrition, Moradabad,
India.
Jan Slezak,
Centre of Experimental Medicine, Institute for Heart Research, Slovak
Academy of Sciences, Bratislava, Slovak Republic.
Please see the link here: https://stm.bookpi.org/CTCB-V4/article/view/7804
